Sophia Genetics Sa SEC Filings

SOPH filed a Form 144 notice for a proposed sale of 3,866 common shares. The shares were acquired as restricted stock units on 10/02/2025 and are slated for sale on or about 10/03/2025 through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ. The filing lists an aggregate market value of $17,281.02 for the proposed shares and notes 67,579,560 shares outstanding.

The notice also details recent Rule 10b5-1 sales over the past three months: 09/19/2025 (381 shares; $1,211.35), 08/19/2025 (380; $1,304.01), 07/23/2025 (66; $226.38), 07/21/2025 (381; $1,349.54), and 07/07/2025 (1,703; $5,155.49).

SOPHiA GENETICS SA insider notice shows a proposed sale of 13,486 common shares, with an aggregate market value of $60,282.42, scheduled for 10/03/2025 on NASDAQ. The securities were acquired as Restricted Stock Units on 10/02/2025 from the issuer and the planned broker is Morgan Stanley Smith Barney LLC.
Recent sales by the same beneficial owner under a Rule 10b5-1 plan are disclosed: five separate sales totaling 10,016 shares between 07/07/2025 and 09/19/2025, generating gross proceeds shown per trade. The filer attests there is no undisclosed material adverse information and references Rule 10b5-1 instruction language in the form.

SOPHiA GENETICS SA insider filing notifies a proposed sale of 6,160 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 10/03/2025 and an aggregate market value of $27,535.20. The shares were acquired as Restricted Stock Units from the issuer on 10/02/2025 and payment/settlement is shown as 10/02/2025. The filing also discloses recent 10b5-1 sales by Daan Guido Maria van Well totaling 4,996 shares sold on 07/07/2025, 07/21/2025, 07/23/2025, 08/19/2025, and 09/19/2025 with combined gross proceeds of $15,599.32. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

SOPHiA GENETICS SA (SOPH) filing a Form 144 notifies a proposed sale of 6,833 common shares with an aggregate market value of $30,543.51 to be sold approximately on 10/03/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 10/02/2025 from the issuer and payment was recorded on 10/02/2025. The filing shows the seller previously completed Rule 10b5-1 sales totaling 5,337 shares across five transactions from 07/07/2025 through 09/19/2025, generating gross proceeds shown per transaction. The Form 144 includes the seller's representation that no undisclosed material adverse information exists and conforms to Rule 144 disclosure requirements.

SOPHiA GENETICS SA (SOPH) filed a Form 144 disclosing a proposed sale of 83,558 common shares through Morgan Stanley Smith Barney with an aggregate market value of $345,094.54 and an approximate sale date of 09/29/2025. The filing shows acquisition details: 42,729 shares as founders' shares acquired 03/18/2011 and 40,829 shares from restricted stock units dated 10/02/2025. The filer also reported multiple recent Rule 10b5-1 sales and an individual sale totaling 40,829 shares on 08/19/2025 with gross proceeds of $142,493.21. The notice includes the required representation regarding absence of undisclosed material information.

SOPHiA GENETICS SA (SOPH) Form 144 notice discloses a proposed sale of 10,415 common shares through Morgan Stanley Smith Barney on 09/26/2025 with an aggregate market value of $35,723.45. The shares were acquired as founders' shares on 03/18/2011. The filing also lists multiple recent dispositions by the same person, including several 10b5-1 plan sales and one direct sale of 40,829 shares on 08/19/2025. Total shares reported sold in the past three months sum to 83,725 shares. The filer affirms no undisclosed material adverse information and references compliance with Rule 10b5-1 where applicable.

SOPHiA GENETICS SA reporting a Form 144 notice: an insider proposes to sell 21,000 common shares through Morgan Stanley Smith Barney on 09/23/2025 on NASDAQ with an aggregate market value of $82,530.00. The shares were acquired 06/24/2024 in a Pre-IPO transaction from the issuer and were paid for on the acquisition date. Total shares outstanding reported are 67,579,560, so the proposed sale equals approximately 0.031% of outstanding shares. The filer certifies no undisclosed material adverse information and provides no other sales in the past three months.

Form 144 filed for SOPHiA GENETICS SA (SOPH) reports a proposed sale of 40,829 common shares through Morgan Stanley Smith Barney with an aggregate market value of $142,493.21, with an approximate sale date of 08/19/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 08/18/2025 and are being sold by the person identified in the filing. The filing also lists multiple prior 10b5-1 sales by the same person between 05/20/2025 and 07/23/2025, showing routine disposals of common shares under a trading plan. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Form 144 notice for SOPHIA GENETICS SA (SOPH) discloses a proposed sale of 6,833 common shares through Morgan Stanley Smith Barney with an aggregate market value of $23,847.17. The filing lists the approximate sale date as 08/19/2025 and shows 67,579,560 shares outstanding. The shares were acquired as restricted stock units from the issuer on 08/18/2025 with payment noted on 08/18/2025. The filing also reports recent 10b5-1 sales by PHILIPPE MENU totaling 6,639 shares across several dates in May–July 2025 with listed gross proceeds.